NCT05456828View on ClinicalTrials.gov

A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

February 10, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Neovascular Age-related Macular Degeneration
Interventions
BIOLOGICAL

ASKG712

ASKG712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.

Trial Locations (1)

Unknown

Shanghai General Hospital, Shanghai

Sponsors
All Listed Sponsors
collaborator

Suzhou Aosaikang Biopharmaceutical Co., Ltd.

UNKNOWN

lead

AskGene Pharma, Inc.

INDUSTRY

NCT05456828 - A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration | Biotech Hunter | Biotech Hunter